Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis

Cell Biochemistry and Function

Volumn 34, Issue 3, 2016, Pages 142-148

  Motawi, Tarek Kamal ^a   Rizk, Sherine Maher ^a   Ibrahim, Taghreed Mahmoud ^b   Ibrahim, Ihab Abdel Rahman ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b Sohage Teaching Hospital   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Bladder cancer; Diagnosis; microRNA; Molecular marker; Prognostic factor; RT PCR

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 143; MICRORNA 92A; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN100 MICRORNA, HUMAN; MIRN143 MICRORNA, HUMAN; MIRN92 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EGYPTIAN; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; BLOOD; GENETICS; MIDDLE AGED; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 84959432583     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3171     Document Type: Article

References (41)

1. Sanchez-Carbayo M. Urine epigenomics: a promising path for bladder cancer diagnostics. Expert Rev Mol Diagnm 2012; 12: 429-432.
2. Zerbib M, Bouchot O. Results of cystectomy for cancer. Prog Urol 2002; 12: 913-922.
3. Rosenberg E, Baniel J, Spector Y, et.al.. Predicting progression of bladder urothelial carcinoma using microRNA expression. BJU Int 2013; 112(7): 1027-1034.
4. Majid S, Saini S, Dahiya R. Wnt signaling pathways in urological cancers: past decades and still growing. Mol Cancer 2012; 11(1): 7.
5. Braicu C, Cojocneanu-Petric R, Chira S, et al. Clinical and pathological implications of miRNA in bladder cancer. Int J Nanomedicine 2015; 10: 791-800.
6. Yang XW, Zhang LJ, Huang XH, et al. miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res 2014; 44: 551-559.
7. Ha TY. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw 2011; 11: 135-154.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
10. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
11. Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumour suppressors. Dev Biol 2007; 302: 1-12.
12. Volinia S, Calin GA, Liu CG, et al. Proc Natl Acad Sci U S A 2006; 103: 2257-2261.
13. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
14. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070.
15. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008; 13: 48-57.
16. Feng Y, Kang Y, He Y, et al. microRNA-99a acts as a tumour suppressor and is down-regulated in bladder cancer. BMC Urol 2014; 14: 50.
17. Witjes JA, Compérat E, Cowan NC, et al. European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014; 65(4): 778-792.
18. Babjuk M, Burger M, Zigeuner R. European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder update 2013. Eur Urol 2013; 64(4): 639-653.
19. Kirschner MB, Kao SC, Edelman JJ, et al. Haemolysis during sample preparation alters microRNA content of plasma PLoS One 2011; 6(9): e24145.
20. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-1330.
21. Jokisch JF, Karl A, Stief C. Intravesical immunotherapy in nonmuscle invasive bladder cancer. Indian J Urol 2015; 31(4): 304-311.
22. Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer 2013; 81(3): 388-396.
23. Matullo G, Naccarati A, Pardini B. MicroRNA expression profiling in bladder cancer: the challenge of next generation sequencing in tissues and biofluids. Int J Cancer. 2015. doi: 10.1002/ijc.29895. [Epub ahead of print].
24. Catto JW, Miah S, Owen HC, at al.. Distinct microRNA alterations characterize high- and lowgrade bladder cancer. Cancer Res 2009; 69: 8472-8481.
25. Tanaka M, Oikawa K, Takanashi M, et al. Downregulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009; 4(5): e5532. 1-5.
26. Ohyashiki JH, Umezu T, Kobayashi C, et al. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes 2010; 3: 347.
27. Ohyashiki K, Umezu T, Yoshizawa S, et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS One 2011; 6(2): e16408. 1-8.
28. Shigoka M, Tsuchida A, Matsudo T, et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 2010; 60: 351-357.
29. Fitchtlscherer S, De Rosa S, Fox H, et al. Circulating microRNs in patients with coronary artery disease. Circulation Res 2010; 107: 677-684.
30. Pignot G, Vieillefond A, Vacher S, et al. Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br J Cancer 2012; 106(6): 1177-1786.
31. Adam L, Wszolek MF, Liu CG, et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol 2013; 31(8): 1701-1708.
32. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou AG. DIANA-mirPath: integrating human and mouse microRNAs in pathways. Bioinformatics 2009; 25: 1991-1993.
33. Oliveira JC, Brassesco MS, Morales AG, et al. MicroRNA-100 acts as a tumour suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev 2011; 12(11): 3001-3004.
34. Wang S, Xue S, Dai Y, et al. Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol 2012; 7: 159.
35. Xu C, Zeng Q, Xu W, et al. MiRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR. Mol Cancer Ther 2013; 12: 207-219.
36. Lin T, Dong W, Huang J, et al. MicroRNA-143 as a tumour suppressor for bladder cancer. J Urol 2009; 181(3): 1372-1380.
37. Noguchi S, Mori T, Hoshino Y, et al. MicroRNA-143 functions as a tumour suppressor in human bladder cancer T24 cells. Cancer Lett 2011; 307: 211-220.
38. Villadsen SB, Bramsen JB, Ostenfeld MS, et al. .The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer 2012; 106: 366-374.
39. Ostenfeld MS, Bramsen JB, Lamy P, et al. MiR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumours. Oncogene 2010; 29: 1073-1084.
40. Liu L, Yu X, Guo X, et al. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumour formation by targeting Bcl-2. Mol Med Report 2012; 5: 753-760.
41. Dong J, Li H, Shao N, et al. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev 2010; 11: 905-911.